| |
Control |
≤55 years |
Secondary Glaucoma |
Previous surgery |
Previous topical therapy |
Re-do surgery |
Trainee surgeon |
| n |
67 |
43 |
40 |
90 |
211 |
66 |
66 |
| Age years |
72 ± 6.7 |
47 ± 8.8*** |
60 ± 17.7*** |
76 ± 7.4*** |
70 ± 7.0 |
73 ± 10.2 |
71 ± 6.2 |
| male:female % |
45/55 |
56/44 |
45/55 |
39/61 |
45/55 |
42/58 |
47/53 |
| Per-operative antifibrotic % 5-FU:MMC |
78 |
93* |
80 |
94*** |
86 |
98*** |
87 |
| 35:65 |
55:45 |
62:38 |
34:66 |
48:52 |
5:95 |
70:30 |
| POAG
NTG %
Other |
67 |
56 |
0 |
62 |
75 |
80 |
71 |
| 27 |
2* |
0 |
19 |
19 |
3** |
11 |
| 1 |
42** |
100 |
15 |
5 |
17 |
18 |
| Presenting highest IOP |
26 ± 5.3 |
34 ± 10.7*** |
44 ± 12.5*** |
28 ± 6.5 |
28 ± 6.5* |
34 ± 9.8*** |
30 ± 9.1** |
| Pre-op IOP |
23 ± 5.1 |
25 ± 8.9 |
31 ± 10.2*** |
23 ± 5.3 |
22 ± 4.9 |
23 ± 5.5 |
23 ± 4.7 |
| Pre-op Rx |
1.4 |
2.2*** |
3.1*** |
2.3*** |
2.5*** |
2.6*** |
2.3*** |
| Final IOP |
12 ± 4.2 |
12 ± 3.9 |
13 ± 5.3 |
12 ± 5.1 |
11 ± 3.3 |
11 ± 3.3 |
13 ± 3.9 |
| Final Rx |
0.3 |
0.6 |
0.4 |
0.2 |
0.3 |
0.5 |
0.6 |
| % Drop from highest IOP |
53% |
61%* |
68%*** |
56% |
58%* |
65%*** |
55% |
| % Drop from pre-op IOP Rx Change |
48% |
47% |
55% |
48% |
47% |
50% |
43% |
| -1.0 |
-1.6 |
-2.7*** |
-2.1*** |
-2.2*** |
-2.0*** |
-1.7** |
| Follow-up months |
54 ± 31.9 |
77 ± 41.2** |
64 ± 37.2 |
53 ± 31.5 |
66 ± 34.3 |
70 ± 32.7** |
70 ± 32.7** |
| n: number of eyes; 5-FU: 5-fluorouracil; MMC: mitomycin-C; POAG: primary open angle glaucoma; NTG: normal tension glaucoma; IOP: intraocular pressure; Rx: mean number of topical anti-glaucoma medications *p<0.05, **p<0.01, ***p<0.001 |
|
